Identification of (R)-1-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a Potent TRPV1 Antagonist for Pain Management

Citations Over TimeTop 10% of 2008 papers

Abstract

Vanilloid receptor TRPV1 is a cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation by several pharmaceutical companies in an effort to identify novel agents for pain management. Here we report that replacement of substituted benzyl groups by an indan rigid moiety in a previously described N-indazole- N'-benzyl urea series led to a number of TRPV1 antagonists with significantly increased in vitro potency and enhanced drug-like properties. Extensive evaluation of pharmacological, pharmacokinetic, and toxicological properties of synthesized analogs resulted in identification of ( R)-7 ( ABT-102). Both the analgesic activity and drug-like properties of ( R)-7 support its advancement into clinical pain trials.

Related Papers

• → N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity(2011)39 cited
• → Capsaicin-induced inhibition of platelet aggregation is not mediated by transient receptor potential vanilloid type 1(2011)25 cited
• → The effects of vanilloid analogues structurally related to capsaicin on the transient receptor potential vanilloid 1 channel(2022)4 cited
• → Understanding the Molecular Determinants of Capsaicin Mode of Action(2015)1 cited
• → Inhibition of platelet aggregation by capsaicin is not mediated by the TRPV1 receptor(2009)